Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Indicated for Treatment of Moderate to Severe Alzheimer's Disease
DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and ... Biopharmaceuticals, Neurology, FDAActavis , Adamas Pharmaceuticals, Namzaric, Alzheimer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 24, 2014 Category: Pharmaceuticals Source Type: news
The real-life Limitless pill? Drug helps adults learn as fast as children by making the brain more 'elastic'
Professor Takao Hensch rewired the brain of a visually impaired women to process images using Alzheimer's drug donepezil. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2014 Category: Consumer Health News Source Type: news
The drug that helps adults learn as fast as children
Professor Takao Hensch rewired the brain of a visually impaired women to process images using Alzheimer's drug donepezil. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2014 Category: Consumer Health News Source Type: news
Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's disease
US-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl to treat moderate to severe Alzheimer's t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 6, 2014 Category: Pharmaceuticals Source Type: news
Forest Files NDA For Alzheimer's Combination Therapy
Forest Laboratories announced it has submitted an NDA to the FDA for the fixed dose combination of memantine HCL extended release and donepezil HCL as treatment for moderate to severe dementia related to Alzheimer’s disease. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 5, 2014 Category: Pharmaceuticals Source Type: news
Could vitamin E slow dementia?
Conclusion
This was a well-conducted randomised controlled trial with a relatively long follow-up period (average two years). The aim was to see whether adding treatment with either a vitamin E supplement, memantine, or the combination, improved functional ability in people with mild to moderate Alzheimer’s disease. And who were also already receiving treatment with licensed acetylcholinesterase inhibitor drugs.
The study found a small though statistically significant difference in the decline of ability to carry out daily tasks in people taking vitamin E compared to placebo. There was also a corresponding small differ...
Source: NHS News Feed - January 2, 2014 Category: Consumer Health News Tags: Neurology Source Type: news
Dr Reddy's launches Alzheimer's drug in US mkt
Dr Reddy's Laboratories today said it has launched generic Donepezil Hydrochloride tablets, used to treat Alzheimer's disease, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 27, 2013 Category: Pharmaceuticals Source Type: news
Novel Agent May Boost Aricept Efficacy (CME/CE)
BOSTON (MedPage Today) -- Adding an investigational agent targeting the 5HT-6 serotonin receptor to donepezil (Aricept) boosted cognition scores relative to donepezil alone in a mid-stage trial, a researcher said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 18, 2013 Category: Consumer Health News Source Type: news
Lu AE58054 as add-on to donepezil
- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the presentation of the first clinical data on the investigational drug Lu AE58054 (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 17, 2013 Category: Drugs & Pharmacology Source Type: news
Aricept Helps Cognition in Parkinson's (CME/CE)
SYDNEY (MedPage Today) -- Parkinson's disease patients who have impaired cognition appeared to benefit from the Alzheimer's disease medicine donepezil (Aricept) with no detriment to their motor skills, researchers reported here. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - June 18, 2013 Category: Psychiatry Source Type: news
Reduced Risk Of Heart Attacks For Patients On Alzheimer's Disease Drugs
Drugs that are used for treating Alzheimer's disease in its early stages are linked to a reduced risk of heart attacks and death, according to a large study of over 7,000 people with Alzheimer's disease in Sweden. The research, which is published online in the European Heart Journal [1], looked at cholinesterase inhibitors (ChEIs), such as donepezil, rivastigmine and galantamine, which are used for treating mild to moderate Alzheimer's disease [2]... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
Alzheimer's Medications Lower Heart Attack And Death Risk
Medications that are prescribed for early-stage Alzheimer's disease appear to reduce the risk of heart attack and early death, researchers from Umeå University, Umeå, Sweden, reported in the European Heart Journal. Professor Peter Nordström and team examined data related to ChEls (cholinesterase inhibitors), including galantamine, rivastigmine and donepezil, all medications used for the treatment of mild-moderate Alzheimer's disease. Cholinesterase inhibitors raise the level of the neurotransmitter acetylcholine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 5, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Drugs used for treating early stages of Alzheimer's 'could also help reduce risk of heart attacks'
Scientists found medication such as Aricept was linked to a 38 per cent cut in the risk of heart attack, compared with people suffering dementia not taking it. (Source: the Mail online | Health)
Source: the Mail online | Health - June 5, 2013 Category: Consumer Health News Source Type: news
Alzheimer’s disease drugs linked to reduced risk of heart attacks
Drugs used for treating Alzheimer’s in its early stages are linked to a reduced risk of heart attacks and death, according to a large study of over 7,000 people with the disease in Sweden published online in the EHJ.The study looked at cholinesterase inhibitors (ChEIs), such as donepezil, rivastigmine and galantamine, which are used for treating mild to moderate Alzheimer's. Read more
Topics:
Acute Coronary Syndromes (ACS) (Source: ESC News and Press)
Source: ESC News and Press - June 4, 2013 Category: Cardiology Source Type: news
